17:55 uur 30-06-2015

Turks ziekenhuis gebruikt Masimo’s SpHb voor constante noninvasieve

Masimo heeft vandaag aangekondigd dat het Turgut Ozal Medical Centre Liver Hospital in de Turkse stad Malatya zijn niet-invasieve technologie voor controle van het hemoglobinegehalte (SpHb) heeft geïnstalleerd. De technologie is bedoeld voor de controle van patiënten die een operatie ondergaan.

SpHb meet constant hoeveel hemoglobine het bloed bevat en maakt veranderingen daarin – of het gebrek daaraan – direct zichtbaar na invasieve afname van bloedmonsters. Hemoglobinewaarden op basis van laboratoriumproeven zijn slechts periodiek beschikbaar en lopen vaak vertraging op. Artsen kunnen bloedverlies inschatten, maar die schattingen kunnen onder of boven het daadwerkelijke bloedverlies liggen.

Turkey’s Leading University Hospital Adopts Masimo SpHb for Continuous Noninvasive Haemoglobin Monitoring

 

Masimo (NASDAQ:
MASI) announced today that
Turgut
Ozal Medical Centre Liver Hospital in Malatya, Turkey, has installed
Masimo’s noninvasive, continuous haemoglobin (SpHb®) technology to
monitor surgical patients.

SpHb
is a breakthrough measurement that noninvasively and continuously
measures total haemoglobin in the blood, and offers real-time visibility
to changes – or lack of changes – in haemoglobin between invasive blood
sampling. Laboratory haemoglobin values are only available
intermittently and are often delayed. Clinicians can estimate blood
loss, but this can both overstate and understate actual blood
loss.1,2

“In many cases with severe bleeding during liver transplantation, we had
to do the blood transfusion on the patient without having the
opportunity to send a sample or the time required to obtain the
results,” said Professor Dr. Hüseyin İlksen Toprak, anaesthesiologist at
Turgut Ozal Medical Centre. “Sometimes, the amount of blood transfused
exceeded that required by the patient. However, today, thanks to routine
SpHb monitoring, I am able to immediately visualise both the level of
bleeding and the therapeutic effect.”

SpHb monitoring may provide additional insight between invasive blood
sampling when:

The SpHb trend is stable and the clinician may otherwise think
haemoglobin is dropping
The SpHb trend is rising and the clinician may otherwise think
haemoglobin is not rising fast enough
The SpHb trend is dropping and the clinician may otherwise think
haemoglobin is stable
“In the area of liver transplantation, Turgut Ozal Medical Centre is
recognised as one of the top five hospitals in the world,” stated Joe
Kiani, Founder and CEO of Masimo. “Their hospital was designed to be one
of the most modern in the country. They had already been using our
SET® Measure-Through Motion and Low Perfusion pulse oximetry. We are
happy to see them adopt SpHb technology through Masimo’s Root® patient
monitoring and connectivity platform.”

The Turgut Ozal Medical Centre is in the campus of the Inonu University.
The hospital has 16 floors, 1024 beds, 31 services, 12 intensive care
units and 26 operating rooms. In addition to liver transplants, the
medical centre also handles kidney transplants, bone marrow transplants
and burn injuries.

In the U.S., Masimo rainbow® SET pulse co-oximeter instruments and
sensors are indicated to provide noninvasive monitoring of arterial
oxygen saturation (SpO2) and pulse rate (PR), carboxyhaemoglobin
saturation (SpCO®), methaemoglobin saturation (SpMet®), total
Haemoglobin concentration (g/dl SpHb), and/or respiration rate (RRa®).
SpHb monitoring is intended to supplement, not replace, laboratory
measurements. Blood samples should be analysed by laboratory instruments
when possible prior to clinical decision making.

@MasimoInnovates
| #Masimo

1 Eipe N et al. Indian Journal of Anesthesia. 2006; 50(1): 35-38.
2
Ram GG et al. Chin J Traumatol. 2014;17(4):225-8.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies that significantly improve patient care-helping
solve “unsolvable” problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET®, which virtually eliminated false alarms and increased pulse
oximetry’s ability to detect life-threatening events. More than 100
independent and objective studies have shown that Masimo SET®
outperforms other pulse oximetry technologies, even under the most
challenging clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced rainbow Pulse
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total haemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhaemoglobin (SpCO®), methaemoglobin (SpMet®), and Pleth
Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion
index (PI). Additional information about Masimo and its products may be
found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo’s unique noninvasive measurement
technologies, including: total haemoglobin (SpHb®) contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions with comparable accuracy and unique advantages,
including: immediate and continuous results that enable earlier
treatment without causing invasive trauma in all patients and in every
clinical situation; as well as other factors discussed in the “Risk
Factors” section of our most recent reports filed with the Securities
and Exchange Commission (“SEC”), which may be obtained for free at the
SEC’s website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today’s date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks
or registered trademarks of Masimo.

src=”http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150629006391r1&si
d=nlnv2&distro=nx&lang=en”/>